Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 241,663 shares of the biotechnology company's stock after acquiring an additional 5,130 shares during the period. Price T Rowe Associates Inc. MD owned 0.25% of Sarepta Therapeutics worth $29,385,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in SRPT. World Investment Advisors LLC purchased a new position in Sarepta Therapeutics during the 3rd quarter worth approximately $2,418,000. Tidal Investments LLC boosted its holdings in shares of Sarepta Therapeutics by 91.2% in the third quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company's stock valued at $704,000 after acquiring an additional 2,688 shares during the period. Garden State Investment Advisory Services LLC purchased a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $2,115,000. GAMMA Investing LLC increased its holdings in shares of Sarepta Therapeutics by 27.7% in the 4th quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company's stock valued at $104,000 after acquiring an additional 185 shares during the period. Finally, Everence Capital Management Inc. purchased a new stake in Sarepta Therapeutics in the 4th quarter valued at $344,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Insider Buying and Selling at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 7.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on SRPT shares. HC Wainwright restated a "neutral" rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, April 16th. Royal Bank of Canada cut Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price objective for the stock from $161.00 to $87.00 in a research report on Monday, March 31st. Deutsche Bank Aktiengesellschaft cut their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research note on Wednesday, March 19th. Wells Fargo & Company initiated coverage on Sarepta Therapeutics in a report on Friday, April 11th. They set an "overweight" rating and a $115.00 price target for the company. Finally, Scotiabank dropped their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a research note on Thursday, March 20th. Six equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $157.95.

Sarepta Therapeutics Price Performance

Shares of SRPT stock traded up $0.73 during trading hours on Friday, hitting $63.51. The company's stock had a trading volume of 1,395,787 shares, compared to its average volume of 1,428,071. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The business has a fifty day moving average of $72.86 and a 200-day moving average of $103.55. Sarepta Therapeutics, Inc. has a twelve month low of $48.01 and a twelve month high of $173.25. The stock has a market cap of $6.24 billion, a price-to-earnings ratio of 50.81 and a beta of 0.93.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.